Tuesday's PR is the 3rd MTA that IPIX has signed t
Post# of 72447
(Total Views: 773)
Posted On: 05/06/2020 12:49:56 AM
Tuesday's PR is the 3rd MTA that IPIX has signed to advance Brilacidin as a treatment and possibly as a key adjuvant component for a successful vaccine for COVID-19. The first was with “a leading US based virology lab", the second with the Regional Biocontainment Lab (RBL) that is currently doing human lung cell testing and today the third MTA with “a leading U.S.-based Public Health Research Institute with access to a Biosafety Level-3 (BSL-3) laboratory”. In addition to these 3 MTA avenues, IPIX has also referenced per the 2/24/20 PR that discussions with both an Asian government-backed lab (which I am guessing is not China) and submitted a summary of Brilacidin for CV19 to BARDA. On 3/6/20 The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants. On 4/6/20 IPIX PRed discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials. Any of the above opportunities could lead to advancing Brilacidin’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications.
Details regarding the above initiatives are attached below. Some of this information was included in a prior post of mine.
====================================================
Note that the first MTA was submitted 2/24/20 with "a leading US based virology lab" and also mentions discussions with an Asian government-backed lab (which I am guessing is not China) and submitted a summary of Brilacidin for CV19 to BARDA which is dedicated to rapidly identifying and funding medical countermeasures to the COVID-19 outbreak.”
The first MTA was signed 3 days later with the RBL on 2/27/20.
The second MTA was signed on 3/6/20 with “a major University with one of the world’s leading coronavirus experts overseeing the research”. The PR also stated “The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants to further evaluate and potentially advance Brilacidin’s clinical development as a novel COVID-19 treatment.”
A 3/10/20 “The Company hopes to disclose the RBL’s research agenda for Brilacidin in the coming days. The upcoming research is being funded by third parties independent of Innovation Pharmaceuticals.” (Why would they use the plural “parties”?)
3/17/20 Details of the second MTA that was announced initially on 3/6/20. This is the first discussion of Brilacidin as an adjuvant for a vaccine.
4/1/20 Successful completion of monkey cell testing with IPIX “In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications.”
4/6/20 “Announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic..”
4/27/20 Details of human lung cell testing for direct virucidal activity Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity); “Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”
5/5/20 “The Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19 to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus.”
Details regarding the above initiatives are attached below. Some of this information was included in a prior post of mine.
====================================================
Note that the first MTA was submitted 2/24/20 with "a leading US based virology lab" and also mentions discussions with an Asian government-backed lab (which I am guessing is not China) and submitted a summary of Brilacidin for CV19 to BARDA which is dedicated to rapidly identifying and funding medical countermeasures to the COVID-19 outbreak.”
The first MTA was signed 3 days later with the RBL on 2/27/20.
The second MTA was signed on 3/6/20 with “a major University with one of the world’s leading coronavirus experts overseeing the research”. The PR also stated “The Company is pursuing pharmaceutical partnerships, academic collaborations and government grants to further evaluate and potentially advance Brilacidin’s clinical development as a novel COVID-19 treatment.”
A 3/10/20 “The Company hopes to disclose the RBL’s research agenda for Brilacidin in the coming days. The upcoming research is being funded by third parties independent of Innovation Pharmaceuticals.” (Why would they use the plural “parties”?)
3/17/20 Details of the second MTA that was announced initially on 3/6/20. This is the first discussion of Brilacidin as an adjuvant for a vaccine.
4/1/20 Successful completion of monkey cell testing with IPIX “In a broader context, demonstration of Brilacidin’s direct antiviral activity against the SARS-CoV-2 virus supports the drug’s unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and its associated complications.”
4/6/20 “Announced today the Company is engaged in discussions with health care provider networks and hospitals both in the United States and Europe regarding options to rapidly advance Brilacidin testing into human trials to evaluate its potential as a novel coronavirus (COVID-19) therapeutic..”
4/27/20 Details of human lung cell testing for direct virucidal activity Determining impact of multiple dose exposure of Brilacidin on SARS-CoV-2 (assessing potential for achieving greater virus control without inducing toxicity); “Concurrently, the Company is prioritizing Brilacidin’s clinical development by taking steps to rapidly advance Brilacidin testing in human trials, including preparations for engaging with regulatory authorities, as the research continues into the drug’s antiviral properties.”
5/5/20 “The Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19 to evaluate Brilacidin’s inhibitory effect on SARS-CoV-2 viral replication in primary immune mediators obtained from both young and old donors to assess age-dependent host responses to the novel coronavirus.”
(18)
(0)